Turnstone Biologics Corp.
TSBX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.01 | -0.01 | 0.04 | 0.00 |
| FCF Yield | -591.13% | -131.08% | -31.23% | -20.09% |
| EV / EBITDA | 0.24 | -0.66 | -7.53 | 3.45 |
| Quality | ||||
| ROIC | -219.51% | -55.13% | -37.64% | 24.38% |
| Gross Margin | 0.00% | 85.50% | 97.00% | 98.01% |
| Cash Conversion Ratio | 0.95 | 1.20 | 2.30 | -1.37 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -42.45% | 4,184,956.49% | 4,661,408.47% |
| Free Cash Flow Growth | -0.39% | 11.58% | -55.46% | 0.00% |
| Safety | ||||
| Net Debt / EBITDA | 0.40 | 0.26 | 1.04 | -3.38 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 5.76 | 5.27 |
| Cash Conversion Cycle | -173.05 | -1.03 | -463.06 | 88.42 |